Abstract: The invention is directed to the therapeutic use of arylsulfonamide derivatives.

Abstract: The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I wherein R, R1, R2, R3, R4, and R5 are as defined; a pharmaceutically acceptable salts thereof; or a pharmaceutically acceptable prodrug esters thereof.

Abstract: Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision.

Abstract: Compositions and regime or regimen for inhibiting unwanted ocular angiogenesis include the treatment of ocular neovascularization by administration of anti-angiogenesis agents, e.g., agents that inhibit VEGF, in combination with a second ocular therapy.

Abstract: The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I wherein R, R1, R2, R3, R4, and R5 are as defined; a pharmaceutically acceptable salts thereof; or a pharmaceutically acceptable prodrug esters thereof.

Abstract: This invention relates to the use of an ascomycin for the treatment of blepharitis.

Abstract: The present invention relates to a fixed combination of a benzo[g]quinoline derivative and a prostaglandin derivative, and their use as pharmaceuticals, especially for treating glaucoma.

Abstract: The present invention relates to novel uses of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders.

Abstract: This invention relates to the use of an ascomycin for the treatment of blepharitis.

Abstract: The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I wherein R, R1, R2, R3, R4, and R5 are as defined; a pharmaceutically acceptable salts thereof; or a pharmaceutically acceptable prodrug esters thereof.

Abstract: The present invention relates to the use of an anti-IgE antibody in the preparation of a topical ophthalmic composition for the treatment of an ocular allergic disorder and a method to treat ocular allergic disorders in a patient in need therefore, which method comprises the topical administration of an opthalmic composition comprising an anti-IgE antibody.

Abstract: The invention concerns an ophthalmic composition comprising a beta-blocker solution, said composition being obtained by dissolving in water beta-blocker in the presence of alginic acid and adding an alkaline base, to obtain a solution with the PH of 6 to 8. Said composition has a sustained duration of action.

Abstract: The subject of this invention is a ready-for-use collyrium intended for the treatment of ocular allergies, comprising, in aqueous solution, mequitazine and a .beta.- or a .gamma.-cyclodextrin optionally etherified by C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 hydroxyalkyl groups, the said cyclodextrin being present in at least a molar ratio of at least one in relation to mequitazine.

Abstract: The object of the invention is an ophthalmic composition containing between 0.1 to 10% by weight of paracetamol in an ophthalmic excipient.

Abstract: The invention relates to a process for the treatment of glaucoma comprising administering to a human in need thereof an effective amount of a compound selected from the inhibitors of xanthine-oxidase.